Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma

Table 4

(a) Biomarker coexpression in blood from healthy women and patients in phases I (before treatment) and II (after treatment)

Biomarker coexpression	Healthy women		Patients				value
			Phase I		Phase II
	Positive		Positive		Positive					1	2	3
	CK19, Ki-67, Myc, CEA	2	6%	13	43%	0	0%	0.00	NS	0.00
CK19, Ki-67, Myc	2	6%	13	43%	0	0%	0.00	NS	0.00
CK19, Ki-67	19	63%	22	73%	10	33%	NS	0.02	0.00

value ≤ 0.05 was considered statistically significant;1 was considered between phase I and healthy women; 2 was considered between phase II and healthy women; 3 was considered between phases I and II.

(b) Biomarker coexpression and its correlation with stage of disease in phases I (before surgery) and II (after treatment)

Biomarker coexpression	Phase I					Phase II
	Stage I		Stages II/III		value	Stage I		Stages II/III		value
	N	%	N	%		N	%	N	%
CK19, Ki-67, Myc, CEA	10	77	3	23	≤0.001	0	0	0	0	—
CK19, Ki-67, Myc	10	77	3	23	≤0.001	0	0	0	0	—
CK19, Ki-67	11	50	11	50	0.006	5	50	5	50	NS

value ≤ 0.05 was considered statistically significant.